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STAT3Increasing evidence reveals a large dependency of epithelial cancer cells on oxidative phosphorylation (OXPHOS)
for energy production. In this study we tested the potential of epigallocatechin-3-gallate (EGCG), a natural poly-
phenol known to target mitochondria, in inducing OXPHOS impairment and cell energy deﬁcit in human
epitheliod (REN cells) and biphasic (MSTO-211H cells)malignant pleuralmesothelioma (MMe), a rare but highly
aggressive tumorwith high unmet need for treatment. Due to EGCG instability that causes H2O2 formation in cul-
turemedium, the drugwas added toMMe cells in the presence of exogenous superoxide dismutase and catalase,
already proved to stabilize the EGCGmolecule and prevent EGCG-dependent reactive oxygen species formation.
We show that under these experimental conditions, EGCG causes the selective arrest of MMe cell growth with
respect to normal mesothelial cells and the induction of mitochondria-mediated apoptosis, as revealed by
early mitochondrial ultrastructure modiﬁcation, swelling and cytochrome c release. We disclose a novel mecha-
nism by which EGCG induces apoptosis through the impairment of mitochondrial respiratory chain complexes,
particularly of complex I, II and ATP synthase. This induces a strong reduction in ATP production by OXPHOS,
that is not adequately counterbalanced by glycolytic shift, resulting in cell energy deﬁcit, cell cycle arrest and ap-
optosis. The EGCG-dependent negative modulation of mitochondrial energy metabolism, selective for cancer
cells, gives an important input for the development of novel pharmacological strategies for MMe.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial bioenergetics and dynamics and their proper regula-
tion are crucial for tumor cell growth. Under normal conditions, cells
rely on mitochondrial oxidative phosphorylation (OXPHOS) to provide
energy for cellular activities. Cancer cells are generally characterized by
a strong enhancement of aerobic glycolysis, the so-calledWarburg effect,
often associated to the decrease in mitochondrial respiration and
OXPHOS [1]. However, it is becoming increasingly evident that enhanced
OXPHOS occurs in a variety of tumors and consequently mitochondria, dichloroﬂuorescein; DCFH-DA,
hin-3-gallate; GLU, glutamate;
itochondrial respiratory chain;
gen species; SOD, superoxide
ator of transcription 3; SUCC,
ltetrazolium bromide.
acca@ibbe.cnr.it (R.A. Vacca).
ights reserved.could be a promising target for the development of efﬁcient anti-
cancer therapies [2–4].
Consistently, it has been recently reported that mitochondria-
targeted molecules, able to disrupt mitochondrial architecture and in-
duce swelling, are effective to reduce the growth of epithelial tumor
cells, such as human breast cancers [5] and malignant mesothelioma
(MMe) [6]. MMe is a rare, but with an increasing incidence, insidious
and highly aggressive cancer with poor prognosis [7]; due to its high
drug resistance, despite the reported improvements in the clinical
management, the unmet need for malignant mesothelioma treatment
is high. Thus, in the light of current failures in MMe therapies, attempts
to induce cell energy deﬁcit can be an attractive strategy to reduceMMe
tumor growth.
In this study we aimed at determining whether epigallocatechin-3-
gallate (EGCG), known to be a mitochondrial-targeted drug [8,9], is
able to induce mitochondrial energy deﬁcit and a selective growth
arrest of MMe cells. EGCG, a natural polyphenol component of green
tea, has been extensively studied for its anticarcinogenic effect in a
wide variety of cancer cells (for Refs. see [10]) and it has been shown
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cell signaling pathways (for Refs. see [12]). Although EGCG targetsmito-
chondria in tumor cells [9], little is known about the effect of EGCG on
mitochondrial function in cancer [13,14].
Another open question is the proper use of EGCG for in vitro studies
necessary to characterize its mechanism of action. It has been shown
that EGCG induces apoptosis in a variety of cultured cancer cell types,
includingMMe cells, through its pro-oxidant activity [15–18]. However,
there is evidence that some of the cytotoxic effects of this compound
may be related to its instability under culture conditions, since, as a
result of its auto-oxidation, oxidative products and reactive oxygen spe-
cies (ROS) are formed in the extracellular phase. The addition of super-
oxide dismutase (SOD) and catalase (CAT) to the culture medium has
been shown to stabilize EGCG and to increase its half-life to more
than 24 h [19–21].
In this study, we emphasize the need to stabilize EGCG in order to
obtain a selective inhibitory action on human MMe-derived REN cells.
Our results disclose for the ﬁrst time a novel mechanism by which
EGCG, through the early impairment of mitochondrial respiratory
chain (MRC) complexes and ATP synthase, induces a strong cell energy
deﬁcit followed by cell cycle arrest in G2/M phase and mitochondria-
mediated apoptosis in MMe cells.
2. Materials and methods
2.1. Cell cultures and materials
The epithelioid MMe derived REN cell line, used as the principal ex-
perimental model in this investigation, is a tumourigenic, p53-mutant,
epithelial subtype [22]. It was characterized and kindly provided by
Dr. Albelda S.M. (University of Pennsylvania, Philadelphia; PA) and
characterized [23]. MSTO-211H, derived from biphasic mesothelioma,
and mesothelial MET5A cell lines were obtained from Istituto Scientiﬁco
Tumori (IST) Cell-bank, Genoa, Italy. Cells were cultured at 37 °C in
humidiﬁed 5% CO2/95% air in RPMI 1640 medium (GIBCO/BRL)
supplemented with 10% heat-inactivated fetal bovine serum (GIBCO/
BRL), 2 mM L-glutamine, penicillin (100 units/ml) and streptomycin
(100 μg/ml) (GIBCO/BRL). Cells were subjected to a 1:3 split every
3 days.
All reagents used were from Sigma-Aldrich unless otherwise
speciﬁed.
2.2. EGCG treatment
EGCG – extracted from green tea leaves with a purity N95% (Sigma-
Aldrich) –was freshly prepared for each experiment at 20 mM concen-
tration in PBS. Cells were seeded into 10-cm Petri dishes, 6-well or
96-well plates, according to the experiment, and cultured until they
have reached 60–70% conﬂuence (about 24 h). For dose-dependent ex-
periments, cells were treated with EGCG (from 20 to 200 μM) added to
the fresh culture medium for 24 h in the absence or presence of SOD
(5 units/ml) and CAT (30 units/ml) [20]. For time-dependent experi-
ments, themedium containing 100 μMEGCG plus SOD and CATwas re-
placed after 24 h of incubation.
2.3. Proliferation assays
Cell proliferation assay was performed by using 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent (XTT, Cell Prolif-
eration Kit II, Roche). 6000 cells per well were seeded into a 96-well
plate and incubated over-night at 37 °C in a CO2 incubator to allow ad-
herence. To assay cell proliferation, 50 μl of XTT labeling mixture were
added to each well and the plate incubated at 37 °C for 2–4 h following
the manufacturer's instructions. Formazan dye accumulation produced
by metabolically active cells was monitored by reading absorbance at490 nm,with a referencewavelength at 655 nm, by using themicroplate
reader mod. 680 (Bio-Rad).
For cell count experiments, cells were seeded at a density of 1 × 106
cells in 10 cm culture plates and incubated over-night at 37 °C. Cells
were then trypsinized, stained with Trypan blue and counted in a
Bürker haemocytometer within 5 min after staining.
2.4. ROS detection
The pro-oxidant dose-dependent response of EGCG was checked by
measuringH2O2 concentration in the culturemediumafter 1 h of incuba-
tionwith different EGCG concentrations either in the absence or presence
of SOD (5 units/ml) plus CAT (30 units/ml), by using Amplex® Red
Hydrogen Peroxide/Peroxidase Assay Kit (Molecular Probes).
Quantitative analysis of intracellular ROS was performed by
means of an LS50 Perkin Elmer spectroﬂuorimeter, using 2′,7′-
dichloroﬂuorescein diacetate (DCFH-DA), a non-ﬂuorescent dye which
is hydrolyzed inside the cells and reacts with multiple types of ROS,
mainly H2O2, to give the ﬂuorescent product, dichloroﬂuorescein
(DCF) [24]. Cultured cells were incubated with 5 μM DCFH-DA for
30 min under growth conditions, washed and suspended in PBS.
Fluorescence emission was recorded at the excitation–emission wave-
lengths of 488 and 520 nm, respectively and normalized to the protein
content to determine the relative ROS production. Protein concentra-
tionwas quantiﬁed by using amodiﬁed Bradford assay (Bio-Rad protein
assay) according to the manufacturer's instructions.
ROSwere visualized in live REN cells by using laser scanning confocal
microscopy imaging. Cells were cultured at low density on ﬁbronectin-
coated 35-mm glass-bottom dishes and treated with 100 μM EGCG in
the presence or absence of SOD and CAT. After 24 h, cells were incubated
for 20 min at 37 °C with both 3 μM DCFH-DA and 3 μM MitoSOX™
(Molecular Probes), a selective mitochondria-targeted probe, speciﬁc
for superoxide anion [25]. After washingwith PBS, stained cells were ex-
amined under a Leica TCS SP5 II microscope (images collected using a
60× objective). The green ﬂuorescence of oxidized DCF was analyzed
by exciting the sample with a Diode 405 laser (λex 488 nm); the red
ﬂuorescence of MitoSOX was analyzed by exciting the sample with a
HeNe laser 543 (λex 543 nm).
2.5. Cell cycle analysis
Cell cycle analysis was carried out by seeding 5 × 105 cells per well
in 96-well cell culture plates in the presence or in the absence of
100 μM EGCG plus SOD (5 U/ml) and CAT (30 U/ml) for 1, 3, 6, 18 and
24 h at 37 °C in a 5% CO2 atmosphere.
After incubation, adherent cells were detached with trypsin (0.5%
trypsin/0.1% EDTA in PBS), harvested in complete RPMI and centrifuged
at 500 ×g for 10 min. Pellets were washed with PBS and ﬁxed with ice-
cold 75% ethanol overnight at 4 °C, treatedwith 100 μg/ml RNase A, and
subsequently stained with 25 μg/ml propidium iodide. Samples were
analyzed by using a ﬂow cytometer FACS (Becton Dickinson) and
ModFit software (Verity Software House).
2.6. Apoptosis assessment
Cells were plated in 96-well culture plates at 6000 cells per well and
incubated over-night at 37 °C in a CO2 incubator to allow adherence.
After 24 h, cells were exposed to EGCG in a culture medium containing
SOD and CAT for an additional 48 h. Apoptosis was measured with the
Cell Death Detection ELISA (Roche), which was performed according
to the manufacturer's protocol. The amount of histone-associated-
DNA-fragments (mono- and oligonucleosomes) was assayed in the
cytoplasmic cell fraction by measuring absorbance at 405 nm, with a
reference wavelength at 655 nm, using the microplate reader mod.
680 (Bio-Rad).
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Cells were lysed with 0.1% Triton X-100 in PBS in the presence of a
protease inhibitor cocktail (Sigma-Aldrich). Cell lysates (0.05 mg pro-
tein) were resolved by a 10%–12% SDS-polyacrylamide gel (depending
on themolecular weight) and transferred to a polyvinylidene diﬂuoride
membrane (Millipore). Membranes were blocked with TBS-T (50 mM
Tris, 150 mM NaCl, 0.02% Tween 20, pH 7.5) containing 5% non-fat
milk and probed with primary antibodies overnight at 4 °C. Immuno-
blot analysis was performed, essentially as described in [26], using
horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibod-
ies and enhanced chemiluminescence Western blotting reagents
(Amersham, Pharmacia Biotech). Membranes were also probed with
anti-β-actin antibody as internal loading control and densitometry
values of immunoreactive bands for each sample were normalized
versus the corresponding densitometry value of β-actin.
2.8. Preparation of mitochondrial and cytoplasmic protein fractions
Cells were trypsinized, washed with ice-cold PBS and centrifuged at
800 ×g for 5 min. Cell pellets were lysed in Buffer A consisting of
20 mM HEPES-Tris (pH 7.6), 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EGTA,
0.1 mMEDTA, 1 mMdithiothreitol, 250 mMsucrose, 10 μg/ml aprotinin,
10 μg/ml leupeptin, 10 mM benzamidine, 1 mM phenylmethylsulfonyl
ﬂuoride (PMSF), and 0.2 mM sodium orthovanadate. Samples were
then homogenized with a Dounce homogenizer (20 strokes for 30 min
on ice) and centrifuged twice at 2000 ×g for 5 min to remove nuclei
and unlysed cells. The ﬁnal supernatant was centrifuged at 13,000 ×g
for 15 min to obtain the mitochondrial fraction (pellet) and the cytosolic
fraction (supernatant).
Supernatants were then centrifuged at 10,000 ×g for 90 min, to ob-
tain a clean cytosolic fraction, while the mitochondrial fraction was
solubilised in Buffer B (1% Triton X-100, 10 mM Tris-HCl (pH 7.4),
150 mMNaCl, 5 mMEDTA, 10 μg/ml of aprotinin, 10 μg/ml of leupeptin,
10 mM benzamidine, 1 mM PMSF and 0.2 mM sodium orthovanadate)
for 30 min on ice.
Mitochondrial and cytosolic fractions were centrifuged at 13,000 ×g
for 10 min and the supernatants were collected and assayed for protein
concentration with the Bio-Rad protein assay method (Bio-Rad). Both
fractions were separated by SDS-PAGE under reducing conditions and
immunoblot analysis was performed as described above.
2.9. Transmission electron microscopy
REN cellswere incubatedwith 100 μMEGCGplus SOD and CAT for 1,
3, 6, 18, 24 or 48 h and then trypsinized and collected by centrifugation.
The cellular pellets were washed in PBS and ﬁxed as previously de-
scribed [27]. Ultrathin sections were placed on Formvar carbon-coated
copper grids, stained with uranyl acetate and lead citrate and observed
under a JEOL 100 SX transmission electron microscope (JEOL, Ltd,
Japan).
2.10. Measurement of MRC complex activities
Measurements of MRC complex activities were carried out in mito-
chondrial membrane-enriched fractions from cultured cells. Aliquots
of trypsinized cells were washed with ice-cold PBS, frozen in liquid
nitrogen and kept at −80 °C until use. Isolation of mitochondrial
membrane-enriched fractions was carried out as described in [28] and
measurement of MRC complex activities performed essentially as in
[29], by three assays which rely on the sequential addition of reagents
tomeasure the activities of: i) NADH:ubiquinone oxidoreductase (com-
plex I) followed by ATP synthase (complex V), ii) succinate:ubiquinone
oxidoreductase (complex II) and iii) cytochrome c oxidase (complex IV)
followed by cytochrome c oxidoreductase (complex III).2.11. Measurement of mitochondrial ATP production
Cells were detached from a 10-cm plate by trypsin treatment,
washed with PBS and suspended in ice-cold sucrose medium (0.25 M
sucrose, 10 mM Tris-HCl pH 7.2, 1 mM EGTA). To measure the mito-
chondrial ATP production, cells (1 mg of protein) were incubated at
37 °C in 2 ml of the respirationmedium (210 mMmannitol, 70 mMsu-
crose, 20 mMTris-HCl, 5 mMKH2PO4/K2HPO4 pH 7.4, 3 mMMgCl2 and
5 mg/ml BSA) and permeabilized with digitonin (0.01% w/v for 5 min).
Then the ATP detecting system (2.5 mM glucose, 2 U hexokinase, 1 U
glucose 6-phosphate dehydrogenase, 0.25 mM NADP+) was added in
the presence of 10 μMdiadenosine pentaphosphate (Ap5A), used to in-
hibit adenylate kinase; the measurement was made in the presence of
either glutamate plus malate (GLU/MAL, 5 mM each) or succinate
(SUCC, 5 mM) plus rotenone (3 μM), used as respiratory energy
sources. Then ADP (0.5 mM) was added and the reduction of NADP+,
which reveals ATP formation, was monitored as an increase in absor-
bance at 340 nm. Care was taken to use enough hexokinase/glucose 6-
phosphate dehydrogenase coupled enzymes to ensure a not-limiting
ADP-regenerating system for the measurement of ATP production.
2.12. Measurement of cellular ATP content
Cells were detached from a 10-cm plate by trypsin treatment,
washed with PBS and cellular ATP content was assayed in cell extracts
obtained by the boiling water procedure as described in [30] by
enzymatic procedure as described in [31].
2.13. Measurement of extracellular L-lactate levels
REN cells were plated in 5-cm dishes, grown until they reached sub-
conﬂuence and incubatedwith 100 μMEGCG plus SOD and CAT for 1, 3,
6, and 24 h. The extracellular L-lactate levels were measured in the cul-
ture medium by using the L-lactate dehydrogenase method, which
gives a reliable estimate of L-lactate production inside the cells [32].
2.14. Statistical analysis
Statistical evaluation was performed by one way ANOVA and
Student's t-test. The threshold for statistical signiﬁcance was set to
P b 0.05.
3. Results
3.1. EGCG, stabilized by SOD and CAT, selectively inhibits MMe REN cell
growth and impairs mitochondrial bioenergetics in a dose-dependent
manner
In order to ascertain the capability of EGCG to selectively inhibitMMe
cell growth, we ﬁrst examined the dose-response effect of EGCG treat-
ment on MMe REN cell proliferation in comparison to that produced
on normal mesothelial MET5A cell proliferation, both in the absence or
presence of SOD and CAT used to prevent EGCG auto-oxidation [18–21].
As shown in Fig. 1A, 24 h-treatment with EGCG selectively inhibited
the growth of theMMe REN cells in a dose-dependent manner when in-
cubated in the presence of SOD/CAT,with an estimated IC50 of 100 μM, as
measured by XTT assay; conversely, the viability of the normal mesothe-
lial MET5A cells was not affected by EGCG in the presence of SOD/CAT.
On the contrary, EGCG proved to inhibit cell growth of both REN and
MET5A cells when added in the absence of SOD/CAT (Fig. 1A).
Importantly, in the absence of SOD/CAT, EGCG induced a dose-
dependent cell death in both REN andMET5A cells (Fig. 1B). On the con-
trary in the presence of SOD/CAT, stabilized EGCG was still able to in-
duce cell apoptosis in MMe REN cells at 100 μM and 200 μM, although
to a less extent than in the absence of SOD/CAT, but completely loss
its pro-apoptotic activity in normal MET5A cells (Fig. 1B).
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Fig. 1. Dose-response effect of EGCG on REN andMET5A cell proliferation and ROS production in the presence or absence of SOD and CAT. MMe REN and MET5A cells were treated with
EGCG at the indicated concentrations either in the absence or presence of SOD (5 U/ml) and CAT (30 U/ml). MMeREN and normalMET5A cells were seeded into 96-well plate and treated
for 24 h with EGCG at the indicated concentrations, either in the absence or in the presence (dotted line) of SOD and CAT. Fresh mediumwas then used to replace the EGCG-containing
medium and (A) cell proliferationwas analyzed by XTT assay and (B) apoptosis wasmeasured by the Cell Death Detection ELISA assay (Roche). (C) Analysis of cellmorphology. Cells were
examined and photographed under phase-contrast microscopy (×400). (D) Production of H2O2 in both REN andMET5A culture medium after 1 h incubation as a function of EGCG con-
centration. Each bar represents mean ± SD (n = 4) for different H2O2 concentrations. (E) Intracellular ROS production in 24 h-treated REN and MET5A cells as a function of EGCG con-
centration. Cells were stained with 5 μM DCF-DA and quantiﬁcation of intracellular ROS was reported as the means (±SD) of DCF ﬂuorescence arbitrary units (A.U.) measured by
ﬂuorimetric analysis. (F) Confocal microscopy imaging of ROS generation and sub-cellular localization in REN cells treated for 24 h with 100 μM EGCG. Images are superimpositions of
10 confocal z-planes and are representative of typical experiment. Each graph is representative of six independent experiments. Signiﬁcant differences between untreated and treated
cells are indicated with asterisks (* = P b 0.05).
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treated with 100 or 200 μM EGCG in the absence or presence of SOD/
CAT showed a reduction in cell density, several cellular debris and signs
of cellular sufferance and in addition, EGCG-treated REN in the absence
of SOD/CAT showed several cytoplasmic vacuoles (Fig. 1C). Similar
changes occurred innormalMET5A cells treatedwith EGCGalone,where-
as in the presence of SOD/CAT, even up to 200 μM EGCG, cells were well
spread and with a ﬂattened morphology, as in non-treated controls.
Since the observed cytotoxic effect of EGCG in the absence of SOD/CAT
could depend on ROS production due to its auto-oxidation [17–21], H2O2
concentration was measured in the culture medium of both EGCG-
treated REN and MET5A cells as a function of EGCG concentration
(Fig. 1D). An increase in extracellular H2O2 concentration was observed
in medium collected from both cell lines starting from 50 to 100 μM
EGCG, almost completely prevented by SOD/CAT addition in both cases.
Thus, ROS scavenging and the consequent stabilization of EGCG by
SOD/CAT in the culture medium, completely prevented EGCG cytotoxici-
ty in normal MET5A cells, but did not reduce the inhibition of MMe REN
cell growth (see Fig. 1A).An increase in intracellular levels of ROS was found in 24 h-treated
REN and MET5A cells starting from 50 μM EGCG, as shown by DCF ﬂuo-
rescence measurements; this ROS overproduction was prevented by the
addition of exogenous SOD and CAT in both cases (Fig. 1E). The intracel-
lular ROS production was also investigated by confocal microscopy anal-
ysis, by incubating REN cells with 100 μM EGCG for 24 h in the absence
or presence of SOD/CAT. Both DCF green ﬂuorescence – revealingmainly
H2O2 production [24] – and MitoSOX red ﬂuorescence – revealing pro-
duction of superoxide frommitochondria [25] –were already detectable
in control cells, and dramatically increased in EGCG-treated REN cells
(Fig. 1F). The presence of SOD/CAT completely prevented the cytoplas-
mic ROS accumulation, while the EGCG-triggered overproduction of su-
peroxide anion by mitochondria remained still substantial.
Since it is well established that the impairment of the mitochondrial
respiratory chain complexes, in particular complexes I and III, induces su-
peroxide anion formation [33], we hypothesized that the overproduction
of mitochondrial ROS in REN cells treated with EGCG stabilized by SOD/
CAT (see Fig. 1E) was a consequence of an EGCG-mediatedmitochondrial
dysfunction. The functional analysis of the mitochondrial respiratory
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in complex activities 24 h after the treatment of REN cells with EGCG sta-
bilized by SOD/CAT (Fig. 2A). Moreover, a remarkable decline in ATP pro-
duction via mitochondrial OXPHOS was observed upon the addition of
the respiratory substrates GLU/MAL or SUCC (Fig. 2B). In addition, the cel-
lular ATP level was decreased in a dose-dependent manner by the stabi-
lized EGCG, becoming 50% lower than that of the untreated cells, with
100 μM EGCG (Fig. 2C). It is interesting to note that no change in both
MRC complex activities and ATP cellular level was observed in normal
MET5A cells incubated with 100 μM EGCG stabilized with SOD/CAT (not
shown).
Altogether these data demonstrate that a 24 h-treatment of REN
cells with stabilized 100 μM EGCG, induces a signiﬁcant impairment of
the MRC function and a decline in the ATP production, selectively in
MMe REN cells.
All the further analysis of EGCG-dependent effects on MMe cells
were carried out incubating REN cell with 100 μMEGCG in the presence
of SOD and CAT.
3.2. EGCG induces cell cycle arrest in G2/M phase and
mitochondria-mediated apoptosis in MMe REN cells
To further investigate EGCG-dependent growth inhibition in MMe
REN cells, cell cycle distribution analysis was performed during the 24-
hour period of EGCG treatment (Fig. 3A). In an early phase (1–6 h) of
the treatment no signiﬁcant changeswere observed in cell cycle distribu-
tion with respect to untreated control cells, after 18/24 h, instead, the
REN surviving population in G2/M phase increased about 3-fold as
compared to untreated cells whose G2/M phase population remained0
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Fig. 2. Dose-dependent effect of stabilized EGCG on MRC complex activities, mitochondrial ATP
with EGCG at the indicated concentrations in presence of SOD and CAT. (A) The activities of CI (c
reductase), CIII (complex III, cytochrome c reductase), CIV (complex IV, cytochrome c oxidase) an
as a percentage with respect to untreated control REN cells. (B) The rate of mitochondrial ATP
(C) The levels of cellular ATP are expressed as nmol/mg cell protein. Each graph is representativ
between untreated and treated cells are indicated with asterisks (* = P b 0.05).unchanged during all the time period investigated (not shown). The
arrest in G2/M was associated with a concomitant decrease in the per-
centage of cells in G0/G1 phase (Fig. 3A).
In parallel, we also evaluated the cell number and apoptosis in EGCG
treated REN cells. After prolonged exposure to EGCG (48 h), a 2-fold de-
crease in cell number (Fig. 3B) and an increase in cell apoptosis (Fig. 3C)
occurred with respect to untreated cells.
Since mitochondria are known to play a central role in eliciting apo-
ptosis in response to many triggers, including EGCG [13,34,35] and
being the mitochondrial release of cytochrome c (cyt c) an early step
in the time course of the events leading to mitochondria-mediated apo-
ptosis [36], we analyzed the distribution of cyt c betweenmitochondrial
and cytosolic fractions during the 24 hour period of EGCG-treatment in
REN cells. The release of cyt c from mitochondria to the cytosol started
6 h after EGCG addition. Cytosolic cyt c level reached about 3-fold
with respect to controls 24 h after the treatment, as shown by immuno-
blotting analysis (Fig. 3D and E).
Ultrastructural observations under transmission electron micro-
scope have been performed to analyze the early and late effects of
EGCG treatment on subcellular cytoarchitecture andmitochondria. Con-
trol REN cells (treated with SOD/CAT from 1 to 48 h) showed an elec-
tron dense cytoplasm rich in ribosomes with several mitochondria,
one or two Golgi apparatus and rare endoplasmic reticulum cisternae
(Fig. 4 A, B). Most of mitochondria showed a dense expanded matrix
and medium/small intracristae compartments, which extend parallel
to the organelle main axis (Fig. 4 A, B). No ultrastructural differences
with respect to controlswere observed in REN cells treatedwith the sta-
bilized EGCG for 1 h (data not shown). Differently, 6 h after treatment,
an accurate analysis of mitochondrial morphology revealed an initial5 50 100
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formation of larger intracristae spaces (Fig. 4C). No additional subcellu-
lar alterations were observable in these samples. Interestingly, 18 h
after the treatment mitochondria ultrastructure resulted highly altered
with almost all mitochondria larger in size with highly enlarged
intracristae compartment (Fig. 4D). 24 h after the treatment some of
the enlargedmitochondria showed pale matrix and in some cases total-
ly disrupted or profoundly disorganized cristae (Fig. 4E, arrows). These
morphological alterations are ascribable to swollen mitochondria that
have lost membrane integrity. Other mitochondria, although provided
with an electrondense matrix, showed marked cristae reorganization,
in particular vesicular cristae that do not attach to the peripheral inner
membrane were observable (Fig. 4E, arrowheads). Finally, 48 h after
the treatment themajority of cells showed clear sign of chromatinmar-
gination a typical feature of apoptotic cell death (Fig. 4F), to conﬁrm the
data shown in Fig. 3C.
3.3. EGCG early affects activity and protein levels ofMRC complexes inducing
MMe REN cell energy deﬁcit
The early ultrastructural modiﬁcation of mitochondria occurring at
6 h after EGCG treatment (see Fig. 4), when neither changes in REN
cell growth nor cell apoptosiswere observed (see Fig. 3 A–C), promptedus to investigate whether EGCG caused early speciﬁc alterations in the
mitochondrial functions. The measurement of MRC complex activities
in mitochondrial membrane-enriched fractions from EGCG-treated
REN cells during the 24 hour period of treatment showed that a signif-
icant reduction inMCR activity already occurred 3 h after the treatment
for complex I, II, IV and ATP synthase (complex V). The activity of all
complexes was reduced of about 50% 18–24 h after the treatment
(Fig. 5A).
To verify whether the EGCG inhibitory effect on the activity of MRC
complexes was associated with changes in their content, the levels of
some OXPHOS complex subunits were analyzed (Fig. 5B). In line with
the functional data, a shared pattern of decrease in the levels of subunits
of all OXPHOS complexes was observed in EGCG-treated REN cells
starting from 3 h after EGCG incubation and involving particularly the
subunits of complexes I, II and V (Fig. 5C), as well as complex IV, as
shown in a representative immunoblot (Fig. 5B), and in the statistical
analysis of densitometry values (Fig. 5C).
To give some insight into themolecular basis of this earlyMRC com-
plexes deﬁcit in EGCG-treated REN cells, we investigated the protein
levels of the phospho-signal transducer and activator of transcription
3 (STAT3) that is known to regulateMRC complex expression and activ-
ity [37] and has been recently reported to be down-regulated by EGCG
in human pancreatic cancer cells [38]. Interestingly, as shown by the
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Fig. 4.Ultrastructural analysis of REN cells treatedwith stabilized EGCG. (A) A control cell treatedwith SOD/CAT for 24 h. N: nucleus, scale bar: 2 μM. (B)Magniﬁcation of the region boxed
in ﬁg. A showing twomitochondria (m), a Golgi apparatus (g) and a portion of the nucleus (N). Scale bar: 0.5 μM. (C) Detail of a cell treatedwith SOD/CAT and 100 μMEGCG for 3 h. Both
normally shapedmitochondria (arrowheads) andmitochondria showing signs of cristae opening (arrows) are visible. m: mitochondria, N: nucleus, scale bar: 0.66 μM. (D) Detail of a cell
treated with SOD/CAT and 100 μM EGCG for 18 h. Large mitochondria with clear signs of cristae disorganization (arrows) are visible. m: mitochondria, N: nucleus, scale bar: 0.66 μM.
(E) Detail of a cell treated with SOD/CAT and 100 μM EGCG for 24 h. Both swollen mitochondria (arrows) and mitochondria showing cristae reorganization (arrowheads) are visible.
m: mitochondria, N: nucleus, scale bar: 0.66 μM. (F) A cell showing condensation and margination of nuclear chromatin 48 h after the treatment with stabilized EGCG. N: nucleus,
scale bar 2.5 μM.
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level was found starting from 3 h after treatment with EGCG with re-
spect to untreated REN cells.
To assesswhether the alterations inMRC complex activities and pro-
tein level have consequences on energy status, the cellular ATP level
wasmeasured in EGCG-treated REN cells. Interestingly, amarked eleva-
tion of cellular ATP amount was found 1 h after EGCG treatment and
was maintained up to 3 h. The ATP amount then gradually declined,
dropping under the level of controls at 24 h (Fig. 6A). This drug-
induced ATP surge is not unusual in cells en route to apoptosis and
could derive from both OXPHOS and anaerobic glycolysis [39,40]. To
check this, we measured both the mitochondrial ATP production and
the extracellular release of L-lactate, the end-product of glycolysis, as
a function of EGCG incubation time. We found that the rate of mito-
chondrial ATP production induced by complexes I and II substrates
(MAL/GLU and SUCC, respectively) increased after 1 h of EGCG incuba-
tion and progressively decreased thereafter, declining under control
values at 3 h of incubation (Fig. 6B). In parallel, we found that levels
of L-lactate strongly increased after 3 h of EGCG treatment (insert of
Fig. 6C) remaining slightly higher with respect to untreated cells at all
the following incubation times (Fig. 6C).3.4. EGCG inhibits mitochondrial metabolism inducing cell energy deﬁcit
and apoptosis in biphasic MMe MSTO-211H cells
In order to conﬁrm the efﬁcacy of EGCG on MMe cell proliferation
and the molecular mechanism by which it acts in these cells, we
checked whether and how 100 μM EGCG stabilized with SOD/CAT in-
duces cell death in MSTO-211H, a biphasic malignant cell line more ag-
gressive than the other MMe cells [41].
Similarly to REN cells, the exposure of MSTO-211H to EGCG up to
48 h inhibited cell growth (Fig. 7A) and determined an increase in cell
apoptosis as compared to untreated cells of 1.6- and 3-folds 24 and
48 h after EGCG treatment, respectively (Fig. 7B). Likewise, analysis of
mitochondrial energy metabolism of EGCG-treated MSTO-211H cells,
showed that both the mitochondrial ATP production induced by com-
plexes I and II substrates (Fig. 7C) and the cell ATP content (Fig. 7D), in-
creased 1 h after EGCG treatment and then progressively reduced up to
24 h. We show that in MSTO-211H, as in the case of REN cells, EGCG
acts via an early impairment of the MRC complexes, being their activity,
in particular that of complex I, II and ATP synthase, already decreased 3 h
after the treatment and reaching a 50% inhibition 24 h after treatment
(Fig. 7E).
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EGCG is a very multifunctional molecule known for its beneﬁcial
effects in a broad range of diseases including neurodegenerative and car-
diovascular diseases [42–45], as well as cancer (for Refs. see [10,46]). In
pathological conditions in which a deﬁcit in OXPHOS is present, as in
the case of Down syndrome, EGCG exerts a cytoprotective effect atlow concentrations (10–20 μM), activating themitochondrial energyme-
tabolism [43]. Conversely, in several cancer types EGCG, used at higher
concentrations, becomes cytotoxic and exerts an inhibitory action on
cell proliferation [10,46,47]; however, studies on the effect of EGCG on
mitochondrial energymetabolism in cancer cells are lacking. Here we re-
port a molecular and functional study which shows for the ﬁrst time that
EGCG, in vitro stabilized with SOD/CAT, selectively induces apoptosis in
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Fig. 6. Energy status in EGCG-treatedMMeREN cells. Cells were treatedwith 100 μMEGCG in presence of SOD and CAT and collected at the indicated time periods. (A) ATP cellular levels were
measured in cell extracts and expressed as nmol/106 cells. (B) The rate of mitochondrial ATP synthesis wasmeasured spectrophotometrically as described in theMaterials andmethods, in the
presence of either glutamate/malate (GLU/MAL) or succinate (SUCC) and expressed as nmol/min/106 cells. (C) Levels of L-lactate were measured in culture medium in both untreated and
EGCG-treated REN and expressed as μmol/106 cells. The inset shows the ratio between themean values of L-lactate level found in EGCG-treated and untreated cells. Graphs are representative
of four independent experiments. Each bar represents mean ± SD. Signiﬁcant differences between untreated and treated cells are indicated with asterisks (* = P b 0.05).
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impairing mitochondrial energy metabolism and leading to cellular ATP
deﬁcit and cell cycle arrest.
It has been recently shown that EGCG can undergo auto-oxidation
causing a dose-dependent ROS production leading to cancer cell apo-
ptosis [15–21]. In the present study, we show that EGCG added to cell
culture medium induces a dose-dependent H2O2 formation and de-
creases the proliferation of both MMe REN and normal mesothelial
MET5A cells to indicate that H2O2 generated from EGCG auto-
oxidation might be responsible for its non-selective cytotoxicity. EGCG
stabilized by SOD and CAT [20,21]which preventH2O2 formation in cul-
ture medium, induces a selective inhibition of MMe REN cell growth
with an IC50 value of 100 μM, without effects on MET5A cells. In addi-
tion, since SOD and CAT cannot cross the plasmamembrane, the signif-
icant decrease in H2O2 intracellular levels observed in the presence of
100 μM EGCG plus SOD/CAT suggests that the stabilized EGCG acts as
a powerful intracellular antioxidant and that the selective inhibition of
MMe REN cell growth by EGCG takes place preventing pro-radical activ-
ity of the drug by its stabilization. Of course under this condition, i.e. in
the absence of extracellular and cytoplasmic ROS, there is a slower in-
duction of cell death than in the presence of non-stabilized EGCG. But
in this latter case we cannot surely afﬁrm that the induction of apopto-
sis, which occurs also in normal mesothelial MET5A cells, was due to
EGCG or to its auto-oxidation products which produce themselves
ROS. These results should be considered in future studies attempting
to elucidate the mechanisms of action of EGCG in vitro systems also in
the light of the observation that oxidation of EGCG does not seem to
occur in vivo since none of EGCG oxidation products were found in the
plasma samples of mice after treatment with EGCG [48].
It should be noted that, as reported in lung cancer cells treated
with EGCG stabilized with SOD/CAT [17], a still evident amount ofmitochondrial ROS is observed in stabilized EGCG-treated REN cells,
probably due to the mitochondrial dysfunction. Consistently, EGCG
treatment of MMe REN cells for 24 h results in a dose-dependent im-
pairment of MRC complex activity. Here we provide indications aiming
to account for the impairment ofMRC complexes found in EGCG-treated
MMe REN cells. In an early phase (3–6 h) of treatment, EGCG promotes
a signiﬁcant general decrease in both activity and protein levels of MRC
complexes, suggesting a regulation at a transcriptional/translational
level. Accordingly, we found a down-regulation by EGCG of STAT3, a
transcription factor known to be involved in the regulation of MRC
complex expression and activity [37]. STAT3 is a proto-oncogene consti-
tutively activated in diverse human cancers including malignant meso-
theliomas [49,50] and known to play a critical role in tumor cell survival,
proliferation, migration, invasion, angiogenesis and inhibition of apo-
ptosis [50,51]. Although some studies reported STAT3 as a negative reg-
ulator of MRC complexes [52,53], recently STAT3was shown to support
oncogenic transformation sustaining MRC activity and blocking mito-
chondrial permeability transition pore [37,54,55]. Consistently with
our results, it has also been reported that EGCG induces a decrease in
STAT3 protein level inhibiting its downstream signaling pathway and
inducing apoptosis in human pancreatic cancer [37]. Here we show
that a down-regulation of STAT3 occurs as a very early event following
EGCG treatment suggesting STAT3 as a primary target of this molecule
in MMe REN cells. Further studies are required to verify whether the
EGCG-dependent STAT3 down-regulation correlates with the impair-
ment of MRC complexes.
EGCG-treated REN cells showa signiﬁcant shortage ofmitochondrial
ATP production, aswell as amarked decline in cellular ATP levels. Given
that a decrease in ATP levels likely affects a variety of vital cellular pro-
cesses, including transcription, translation and signal transduction, it is
noticeable to ﬁnd REN cell cycle arrest. Furthermore, following the cell
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2094 D. Valenti et al. / Biochimica et Biophysica Acta 1832 (2013) 2085–2096cycle arrest, EGCG-treatedMMe REN cells show typical signs of apopto-
sis, such as histone-associated-DNA-fragmentation and nuclear chro-
matin margination. Drug-induced G2/M arrest followed by apoptosis
occurs in a variety of tumor types of both epithelial and hematologic
cell origin [56]. Interestingly, ultrastructural mitochondrial changes,
such as cristae opening and mitochondrial swelling, as well as cyt c re-
lease by mitochondria, occur only 6 h after EGCG treatment when no
signs of apoptosis are detectable, indicating that EGCG induces
mitochondrial-mediated apoptosis in MMe REN cells.
The results reported in this paper shed a new light on some aspects
of energy metabolism in EGCG-treated MMe cells. In the early phase of
EGCG treatment (1–3 h), an increase in the ATP level occurs which
derives from both anaerobic glycolysis and oxidative phosphorylation,as revealed from the increased L-lactate levels and the still efﬁcient mi-
tochondrial ATP production. This early cellular ATP surge might be a
trigger to initiate the programmed cell death [39,40] or even a
cytoprotective mechanism of resistance to chemotherapeutic agents
[57]. In the late phase of EGCG treatment (18–24 h),when the oxidative
phosphorylation is strongly impaired, cellular ATP level strongly de-
creases suggesting that the energy shift towards glycolysis is no more
sufﬁcient to maintain the energy demand, and MMe cells proceed to-
wards cycle arrest and then apoptosis.
These data have been conﬁrmed in cells derived frombiphasicMMe,
theMSTO-211H cell linewhich appeared to be evenmore sensitive than
REN (epithelioid)MMe cell line to the growth-inhibitory effect of EGCG,
probably due to the highly aggressive nature of MSTO-211H cells [41].
2095D. Valenti et al. / Biochimica et Biophysica Acta 1832 (2013) 2085–2096Interestingly, MSTO-211H cells showed a very high mitochondrial me-
tabolism being both mitochondrial ATP production and ATP cellular
level in basal condition (i.e. without EGCG treatment) about 4-fold
higher than that observed in REN (compare Figs. 7 and 6) supporting
the hypothesis of a correlation between enhanced OXPHOS and tumor
proliferation in MMe as described in other tumor types [2–4].
Our results provide evidences supporting the use of EGCGas adjuvant
in combination with other chemotherapic agents with proven efﬁcacy
onMMe cells such as gemcitabine, as proposed in [58], to be tested in ex-
perimental earlier phases of clinical trials. Moreover, it can be hypothe-
sized that a local infusion of EGCG might help in preventing recurrent
pleural effusion in patients with advanced disease.
In conclusion, the present report suggests that EGCG, aswell as other
agents that inhibitMRC complex activities and energymetabolism,may
provide reliable therapeutic options for the management of MMe and
may be useful in the treatment of malignant tumors.Acknowledgements
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